E3330 Benzoquinone Selective Ape1/Ref-1 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with altered angiogenesis, such as cancer and cardiovascular diseases, are inadequate in effectively inhibiting the redox function of Ape1/Ref-1, which contributes to angiogenesis and tumor progression.
Innovation Solution
The use of 3-[(5-(2,3-dimethoxy-6-methyl-1,4-benzoquinoyl)]-2-nonyl-2-propenoic acid (E3330) selectively inhibits the redox function of Ape1/Ref-1, thereby acting as an anti-angiogenic agent without affecting its BER function, and can be administered alone or in combination with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Ape1/Ref-1 redox function is inhibited to suppress angiogenesis and tumor progression, then anti-angiogenic activity is improved, but DNA base excision repair function may be affected causing genomic instability
Solution Approach 1:
The invention segments the dual-function Ape1/Ref-1 enzyme into two separate therapeutic targets: one component selectively inhibits the redox function to suppress angiogenesis and tumor progression, while another component preserves or enhances DNA base excision repair function to maintain genomic stability. This functional segmentation allows independent optimization of anti-angiogenic activity while avoiding genomic instability side effects.
Solution Approach 2:
The invention introduces a selective inhibitor as an intermediary agent that specifically targets the redox effector domain of Ape1/Ref-1 without interfering with its DNA repair activities. This intermediary molecule acts as a bridge to achieve therapeutic anti-angiogenic effects while preserving essential genomic repair functions, thereby resolving the contradiction between anti-tumor activity and genomic stability.
2Productivity
If conventional anti-angiogenic treatments are used, then tumor growth is partially inhibited, but they fail to effectively inhibit the redox function of Ape1/Ref-1 leading to inadequate therapeutic effect
Solution Approach 1:
The invention changes the molecular parameters of anti-angiogenic therapy by introducing a compound with specific chemical structure and properties that enable selective inhibition of Ape1/Ref-1 redox function. This parameter change at the molecular level translates to improved therapeutic efficacy in inhibiting tumor growth and angiogenesis, overcoming the limitations of conventional treatments that cannot effectively target the redox function.
3Stability of the object's composition
If Ape1/Ref-1 expression is increased to enhance DNA repair, then genomic stability is improved, but angiogenesis and tumor progression are accelerated
Solution Approach 1:
The invention segments the regulatory control of Ape1/Ref-1 into two independent pathways: one pathway allows increased expression or activity for enhanced DNA repair and genomic stability, while another pathway selectively inhibits the redox effector function to prevent angiogenesis and tumor progression. This segmentation enables simultaneous achievement of genomic stability and anti-angiogenic effect by decoupling the two functions.
Solution Approach 2:
The invention applies local quality control by selectively modulating the redox effector domain of Ape1/Ref-1 while preserving its DNA repair functions in different cellular contexts. This localized intervention allows the enzyme to maintain genomic stability through DNA repair activities while its redox function is locally inhibited to prevent harmful angiogenesis, resolving the contradiction between these two outcomes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
E3330 effectively decreases VEGF release, impairs capillary tube formation, and inhibits the growth of cancer cells, demonstrating significant anti-angiogenic activity while sparing normal cells, and can be administered via various routes for therapeutic and prophylactic purposes.
Implementation Method 1
Ape1/Ref-1 also functions as a redox effector maintaining transcription factors in an active reduced state
Implementation Method 2
E3330 effectively decreases VEGF release, impairs capillary tube formation, and inhibits the growth of cancer cells, demonstrating significant anti-angiogenic activity
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Apel/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present invention describes the use of agents to selectively inhibit the redox function of Apel/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Apel/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Apel/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component.